...
首页> 外文期刊>Clinical and experimental allergy : >Performance of a component-based allergen-microarray in the diagnosis of cow's milk and hen's egg allergy.
【24h】

Performance of a component-based allergen-microarray in the diagnosis of cow's milk and hen's egg allergy.

机译:基于成分的过敏原微阵列在诊断牛奶和鸡蛋过敏方面的性能。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The food challenge test (FCT) is the gold standard for the diagnosis of food allergy. This procedure is time consuming, costly and can induce potentially severe symptoms. An ideal in vitro test should allow to avoid the FCT. Objective To assess the clinical performance of microarray for specific IgE (sIgE) detection in children with challenge-proven/excluded cow's milk (CM) or hen's egg (HE) allergy. METHODS: One-hundred and four children with suspected IgE-mediated hypersensitivity to CM or HE were studied. In all patients, skin prick test, ImmunoCAP, microarray and FCT were performed. RESULTS: The microarray components Bos d 8 for CM (27/58 patients) and Gal d 1 (20/46 patients) and Gal d 2 (24/46) for HE were the most frequently recognized allergens. Using the FCT results as the reference parameter, sIgE to Bos d 8 and Gal d 1 had the highest area under the curves. These were not significantly different from those obtained using the ImmunoCAP. Use of 95% clinical decision points (CDP) for sIgE to Bos d 8 and Gal d 1 resulted in higher negative predictive values (78% and 79%, respectively) than those obtained with the ImmunoCAP (57% and 59%). CONCLUSIONS: Our results show that in children with suspected CM or HE allergy, the microarray has a good ability to predict the FCT results. In a clinical application perspective, the microarray could be used as a second-level assay, if the ImmunoCAP sIgE is <95% CDP. This approach would lead to a decrease in the number of the FCT to be performed, as well as of positive FCTs with a subsequent decrease in severe reaction risk.
机译:背景:食物激发试验(FCT)是诊断食物过敏的金标准。该过程耗时,昂贵并且会引起潜在的严重症状。理想的体外测试应避免使用FCT。目的评估在挑战验证/排除的牛奶(CM)或鸡蛋(HE)过敏儿童中进行特异性IgE(sIgE)检测的微阵列的临床性能。方法:研究了一百零四名怀疑是IgE介导的对CM或HE过敏的儿童。在所有患者中,进行了皮肤点刺试验,ImmunoCAP,芯片和FCT。结果:CM(27/58例)和Gal d 1(20/46例)和Gal d 2(24/46)的微阵列成分Bos d 8是最常见的过敏原。使用FCT结果作为参考参数,到Bos d 8和Gal d 1的sIgE在曲线下面积最大。这些与使用ImmunoCAP获得的无明显差异。对Bos d 8和Gal d 1使用sIgE的95%临床决策点(CDP)导致的阴性预测值(分别为78%和79%)高于ImmunoCAP的阴性预测值(57%和59%)。结论:我们的结果表明,在怀疑患有CM或HE过敏的儿童中,微阵列具有很好的预测FCT结果的能力。从临床应用的角度来看,如果ImmunoCAP sIgE <95%CDP,则微阵列可用作二级检测。这种方法将导致要执行的FCT数量以及阳性FCT数量的减少,从而降低严重的反应风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号